semaglutide fatty liver disease (Wegovy) Improves MASH in Ongoing Study Semaglutide treats MASH liver disease

It targets the bodys fat burning receptors and triggers the body to increase temperature and activate fat burning

If gut dysfunction contributes to metabolic problems, improving gastrointestinal health could theoretically support weight management

Novo Nordisk Unveils New Strength of Wegovy With Significant Weight Loss Results Novo Nordisk, a leading pharmaceutical company, has announced plans to seek approval from the UKs Medicines and Healthcare products Regulatory Agency (MHRA) for a new 7.2mg dose of its weight-loss drug Wegovy (semaglutide)

Current evidence only confirms its role in stimulating growth hormone, not visible anti-aging effects

Summary: Wegovy is not recognised to cause nightmares in official UK prescribing information or large-scale clinical trials, though some anecdotal reports exist

What are the benefits of taking retatrutide